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doi:10.1016/j.ejvs.2010.05.007Abstract Objectives: We sought to evaluate whether clinical, lesion-related and procedural
factors may predict in-stent restenosis (ISR) after intracranial stenting.
Methods: Sixty-one Chinese patients with 65 lesions treated with single bare metal balloon-
mounted stent for symptomatic intracranial arterial stenosis underwent conventional angio-
graphic follow-up after procedures between March 2004 and July 2009. Clinical, lesion-related
and procedural factors were analysed for any predictive power for the ISR using univariate and
multivariate analysis. ISR was defined as >50% stenosis within or at the edge of the stent or
absolute luminal loss >20%.
Results: ISR was found in 18 patients (18/61, 29.5%) with 20 lesions (20/65, 30.8%) at a median
follow-up of 7 months (range, 5e30 months). Univariate analysis revealed that diabetes, Mori
classification, lesion length and stent diameter were associated with ISR. In addition, diabetes
(hazard ratio (HR), 2.661; 95% confidence interval (CI), 1.044e6.787; PZ 0.040) and lesion
length (HR, 1.206; 95% CI, 1.023e1.421; PZ 0.026) were detected as two independent predic-
tors for ISR by stepwise multivariate Cox regression analysis.
Conclusions: ISR after intracranial stenting with bare metal balloon-mounted stents in our
series seems to be more frequent than those reported by the majority of the published case
series. Diabetes and lesion length are associated with increased risk of ISR.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.84801861; fax: þ86 25 84664563.
.cn (X.F. Liu).
this work.
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500 S.G. Zhu et al.Atherosclerotic stenosis of the major intracranial arteries is
a high-risk cause of ischaemic stroke, which accounts for
30e50% of strokes in Asia1 and 8e10% in North America2
each year. The WarfarineAspirin for Symptomatic Intra-
cranial Disease study (WASID) revealed that despite best
anti-thrombotic therapy, the rate of ischaemic stroke ipsi-
lateral to the intracranial high-grade (50e99%) stenotic
artery was nearly 12% at 1 year3 and the risk for a subse-
quent stroke was highest in the subgroup of patients with
a stenosis >70%.4 For these reasons, patients with symp-
tomatic high-grade stenoses intractable to medical therapy
might benefit from an interventional therapy.
A major concern for using bare metal stents for symp-
tomatic intracranial stenosis has been the rate of in-stent
restenosis (ISR), reported to be as high as 32%.5 The path-
ogenesis of ISR remains poorly understood and identifying
the predictors for ISR may allow some insights into the
underlying ISR mechanisms. Furthermore, because ISR is
associated with a high rate of recurrent neurologic events
(transient ischaemic attack (TIA) stroke or death),5,6 the
identification of risk factors can help to predict ISR after
stent placement. A few clinical and anatomic characteris-
tics correlating with ISR after intracranial stent placement
have been reported previously.5,7e9 However, there are no
data on lesion characteristics as a predictor of ISR. In the
present study, we analysed the value of different depen-
dent variables in predicting ISR including clinical and
procedural variables, and lesion-related characteristics,
including the Mori classification.10,11
Patients and Methods
Study patients
This retrospective analysis and the protocol of this study
received the approval of our institutional review board.
Written informed consent was obtained from each patient
prior to the initial procedure and follow-up angiography.
Nanjing Stroke Registry Program (NSRP) with a stand-
ardised protocol12 included and identified a total of 84
patients who failed optimal medical therapy of symptom-
atic intracranial atherosclerotic stenosis (50%) and then
underwent attempted treatment with a single bare metal
balloon-mounted stent at Jinling Hospital between March
2004 and July 2009. Failure of optimal medical therapy was
defined as recurrent stroke or TIA despite treatment with
anti-platelet therapy (aspirin, clopidogrel or a combination
thereof) and a cholesterol-lowering agent (statin). Patients
beyond at least 7 days of an ischaemic stroke were advised
to receive stenting if necessary in our centre. Among the 84
patients who had 90 intracranial atherosclerotic lesions
treated with single bare metal balloon-mounted stent, 61
patients with 65 lesions had angiographic follow-up at
a median of 7 months (range, 5e30 months) after the
procedure and are the focus of this study.
Definition
Using the WASID technique,3 ISR was defined as a lesion
demonstrating >50% stenosis with or at the edge of the
stent; or absolute luminal loss >20% at angiographic follow-up when some lesions were left with residual stenosis
measuring between 30% and 50% after the initial
treatment.13
In the Mori classification system, atherosclerotic lesions
are classified into three groups by length and geometry.10,11
Mori A lesions were short (<5 mm in length), concentric or
moderately eccentric, less than totally occlusive. Mori B
lesions were tubular (5e10 mm in length), extremely
eccentric or total occlusive, and less than 3 months old, and
Mori C lesions were diffuse (>10 mm in length), extremely
angulated (>90) or total occluded and 3 months old or
older. The morphologic characteristics of lesions identified
by angiography were defined in accordance with the
American Heart Association/American College of Cardi-
ology classification as modified by Ellis et. al.14 Lesion
length was measured as the distance between proximal and
distal shoulders of the original lesion (before the proce-
dure). Lesion ulceration was considered present if luminal
contour were markedly irregular with overhanging margins
or a small crater. A lesion was considered as eccentric if its
lumen was in the outer one-quarter diameter of the
apparent normal lumen. A lesion was classified as having an
irregular contour if the vascular margin was rough or had
a ‘sawtooth’ appearance.
Stent size (length and diameter) was defined as the
actual implanted stent size. Excess stent length was
defined as the remaining length of lesion length subtracted
from stent length for each target lesion.Stent-placement techniques
After induction of general anaesthesia or local anaesthesia,
a 6-French guiding catheter (‘Envoy’, Cordis, USA; ‘Guider
softtip XP’, Boston Scientific, Natick, MA, USA) was advanced
to the distal cervical internal carotid artery or vertebral
artery through a 6-French femoral arterial sheath. Under
roadmap guidance, a 0.014-inch microwire (‘Luge’, ‘Choice
PT’, ‘PT Graphix’, or ‘PT2’, Boston Scientific, Natick, MA,
USA) was carefully steered through the target lesion and was
fixed distally to support the delivery of the stent system. If
the diameter of the stenotic lesion was considered to be
smaller than the profile of the stent catheter, pre-dilatation
was performed with an undersized balloon (‘Maverick’,
Boston Scientific, Natick, MA, USA). The following baremetal
balloon-expandable stents with different diameters and
lengths were used to treat the lesions of variable sizes in this
study: ‘Invastent VOLO’, Invatec, Brescia, Italy; ‘Jostent
flexmaster’, JOMED GmbH, Rangendingen, Germany; ‘Amg’,
AMG Raesfeld-Erle, Germany; and ‘Apollo’, MicroPort
Medical, Shanghai, China. Stents were sized to match the
diameter of the smallest normal adjacent vessel and to cover
the entire length of the atherosclerotic lesion. The stents
were deployed with the slow inflation of the balloon to its
nominal pressure over a period of 30 s. Technical success was
defined as the complete coverage of the lesionwith less than
50% residual stenosis.
Heparin was given to all of the patients intra-
procedurally to achieve a target activated clotting time of
250e300 s. All patients were pretreated with 100 mg
aspirin and 75 mg clopidogrel daily for at least 3 days
before the intervention and were discharged on the same
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dual anti-platelet regimens for at least 6 months after
stent implantation. Provided that no ISR had developed,
clopidogrel was withdrawn and aspirin continued
indefinitely.
Clinical and angiographic follow-up
Clinical follow-up information was obtained on each
patient through review of medical records, personal inter-
view or telephone contact at 1, 3, 6 and 12 months, and
yearly thereafter. All neurologic events were recorded as
clinical end points, including any death, TIA or stroke with
30 days after the initial procedure.
All patients were informed of an angiographic follow-up
at 6 months after the initial procedure, or earlier in the
case of either recurrent TIA or acute ischaemic stroke. ISR
was recorded as an angiographic end point. The patients
with symptomatic ISR were encouraged to undergo
attempted repeat angioplasty with/without stent
placement.
Angiographic assessment
Quantitative angiographic analysis was performed before
and immediately after the procedure, and at the follow-up
by two experienced operators blinded to the study purpose
using the GE Advanced Workstation (AW 4.2_0.4). Matched
views were selected for angiograms recorded. Lesion
length, reference diameter (RD) and minimum lumen
diameter (MLD) were measured before and immediately
after stenting and at follow-up using the contrast-filled
guiding catheter as the reference standard. The other
variables obtained were lesion contour (irregular or
smooth), lesion eccentricity or concentricity and lesion
ulceration. The degrees of the initial and residual stenosis
were calculated using the WASID technique.3Table 1 Patient characteristics.




Age, years 58.82 11.67 60.96




Smoking (any time) 36/84(42.9) 8/23(3
Coronary artery disease 16/84(19) 4/23(1
Qualifying event
TIA 26/90(28.9) 7/25(2
Ischaemic stroke 64/90(71.1) 18/25(7
Lesion location
Anterior circulation 56/90(62.2) 13/25(5
Posterior circulation 34/90(37.8) 12/25(4
Degree of stenosis, % 74.81 10.02 77.82
Lesion length (mm) 6.50 2.55 6.82
Abbreviations: TIA, transient ischaemic attack.
Data are expressed as mean S.D. or number (%).Data collection and analysis
Clinical and angiographic data at the time of the initial
procedure and during follow-up thereafter were collected
from the NSRP.12 On the basis of earlier experience with
primary angioplasty and stent treatment, some potential
variables for restenosis were chosen and listed in Tables
2e4. Univariate and multivariate analyses to assess asso-
ciations of these variables with ISR were performed.
Continuous data are presented as mean  standard devi-
ation; categorical data are presented as the count
(percentage). Continuous variables were compared using
unpaired Student’s t-test and categorical data with Fisher’s
exact test. Cross tables (2 2) were constructed to calculate
the risk ratio (RR) with 95% confidence intervals (CIs) for the
development of ISRwith clinical, angiographic andprocedural
variables. To control for the errors that resulted frompossible
deviations of the continuous variables from a normal distri-
bution, this analysiswas verified by theManneWhitneyU test,
which produced similar results. A multivariate Cox regression
model with stepwise removal of non-significant variables was
used to identify predictors for ISR. The variables listed in
Tables 2e4 were entered in the stepwise multivariate Cox
regression analysis. The entry and removal probability of
stepwise selection were 0.1 and 0.2, respectively. A P value
<0.05 was considered statistically significant. We performed
a KaplaneMeier survival analysis on ISR and neurologic events
during follow-up (including any death, TIA or stroke within 30
days of the initial procedure). All statistical analyses were
performedusingSPSSversion 15.0 (SPSS Inc,Chicago, IL, USA).
Results
During a 5-year period, a total of 84 patients with 90
intracranial atherosclerotic lesions underwent attempted
treatment with single bare metal balloon-mounted stents.
The mean age of the patients was 58.8 11.7 years (range,iographic follow-up
procedures in 23 patients
Angiographic follow-up nZ 65














Table 2 Clinical variables at baseline vs. risk of ISR during angiographic follow-up.
Total ISR, n (%) Risk ratioa P
Patient characteristicsb nZ 61 nZ 18 (95% CI)
Age (years)
<65 39 9(23.1) 2.308(0.745e7.145) 0.143
65 22 9(40.9)
Sex
Male 49 13(26.5) 1.978(0.533e7.340) 0.313
Female 12 5(41.7)
Hypertension
No 14 4(28.6) 1.061(0.284e3.960) 1.000
Yes 47 14(29.8)
Diabetes
No 35 6(17.1). 4.143(1.287e13.339) 0.014
Yes 26 12(46.2).
Hypercholesterolemia
No 35 9(25.7) 1.529(0.505e4.631) 0.451
Yes 26 9(34.6)
Smoking (any time)
No 33 7(21.2) 2.403(0.778e7.423) 0.123
Yes 28 11(29.3)
Coronary artery disease
No 50 14(28) 1.469(0.372e5.811) 0.717
Yes 11 4(36.4)
QE
TIA 19 6(31.6) 0.948(0.299e3.004) 0.928
Ischaemic stroke 46 14(30.4)
Time from QE to stenting (days)
<25 32 9(28.1) 1.278(0.444e3.678) 0.649
25 33 11(33.3)
Abbreviations: TIA, transient ischaemic attack; QE, Qualifying event; CI, confidence interval.
Data are expressed as number (%).
a Risk ratio for second group relative to the first.
b QE and time from QE to stenting were calculated by total number lesions stented (65).
502 S.G. Zhu et al.36e80 years), and 78.6% were male. The qualifying events
before stenting were ischaemic strokes in 71.1% and TIAs in
28.9%. The median interval between the qualifying event
and procedure was 25 days (range, 7e280 days). Patient
characteristics are presented in Table 1.
The overall success rate of stent delivery was 87 of 90
lesions (96.7%). The lesion locations with failure to delivery
were inone intracranial internal carotidarteryandonemiddle
cerebral arterybecause the stentscouldnotcross the tortuous
vessels. In addition, unsuccessful reduction of the stenosis to
<50% occurred in one patient because of a heavily calcified
intracranial carotid lesion. The mean stenosis before treat-
ment was 74.81 10.02%, with a reduction of stenosis to
18.84 8.25% immediately after the stenting.
The rate of stroke and/or death within 30 days was
4.76% (4/84). The one death was due to a major stroke 2
weeks after stenting. All nonfatal complications included
two ischaemic strokes (caused by perforator occlusion) and
one intracranial haemorrhage (hyperperfusion related).
There were no TIAs within 30 days.
Clinical and angiographic outcome during follow-up
All patients who survived the first month were followed up
clinically. Median follow-up time was 9 months (range,3e58 months). Recurrent neurologic events occurred in six
patients: four had a TIA and two had a stroke. Only one
patient died due to pneumonia. KaplaneMeier survival
analysis revealed that neurologic event-free survival was
82.9% at 24 months after stenting (Fig. 1).
Catheter-based angiographic follow-up was available
for 61 patients with 65 lesions at a median of 7 months
(range, 5e30 months). More than 90% of angiographic
follow-up evaluations were performed between 6 and 10
months. Only one lesion was imaged at less than 6 months
after stent placement. Twenty-three patients with 25
stents did not have angiographic follow-up. Baseline
characteristics for the subsets of patients with or without
angiographic follow-up were similar (Table 1). Eighteen
patients (18/61, 29.5%) with 20 lesions (20/65, 30.8%)
were found to have ISR. However, using the KaplaneMeier
method, the cumulative 12-month ISR rate was 50.6%. By
10 months, all ISR had occurred in this study (Fig. 2). Of
18 patients with ISR, three were symptomatic, but others
were asymptomatic. One patient presented recurrent
ischaemic stroke due to completely in-stent thrombosis
subsequent to ISR at 7 months after stenting. The other
two patients experienced TIAs. The three patients
refused to be retreated with angioplasty or stent
placement.
Table 3 Lesion variables vs. risk of ISR during angiographic follow-up.
Lesion characteristics Total ISR, n (%) Risk ratioa P
nZ 65 nZ 20 (95% CI)
Lesion location
Anterior circulation 43 13(30.2) 1.077(0.355e3.262) 0.896
Posterior circulation 22 7(31.8)
Mori classificaton 0.023
Mori A 25 3(12) 1
Mori Bb 32 13(40.6) 5.018(1.241e20.295)
Mori Cb 8 4(50) 7.333(1.168e46.052)
Ulceration
No 55 16(29.1) 1.625(0.040e6.541) 0.482
Yes 10 4(40)
Eccentricity
No 38 9(23.7) 2.215(0.759e6.470) 0.142
Yes 27 11(40.7)
Irregular contour
No 37 8(21.6) 2.719(0.921e8.030) 0.066
Yes 28 12(42.9)
ISR No ISR
nZ 20 nZ 45
Lesion length (mm) 7.52 2.65 5.87 2.14 0.009
Reference diameter (mm) 3.55 0.78 3.66 0.92 0.643
Degree of stenosis (%) 73.62 10.62 72.92 9.91 0.831
Degree of residual stenosis (%) 21.85 8.51 18.87 8.86 0.207
Abbreviations: CI, confidence interval.
Data are expressed as mean S.D. or number (%).
a Risk ratio for second group relative to the first.
b vs. less than Mori A.
Table 4 Procedural variables vs. risk of ISR during angiographic follow-up.
Procedural characteristics Total ISR, n (%) Risk ratioa P
nZ 65 nZ 20 (95% CI)
Type of Anaesthesia
Conscious sedation 57 18(31.6) 0.722(0.133e3.934) 1.000
General sedation 8 2(25)
Brand of stentb 0.699
Invastent VOLO 27 7(25.9) 1
Apollo 21 6(28.6) 1.143(0.318e4.109)
AMG 3 1(33.3) 1.429(0.112e18.298)
Jostent flexmaster 14 6(42.9) 2.143(0.548e8.385)
Stent lengthc (mm) 0.295
7 16 2(12.5) 1
8 15 4(26.7) 2.545(0.391e16.550)
9 14 6(42.9) 5.250(0.850e32.430)
10 3 1(33.3) 3.500(0.208e58.770)
>10 17 7(41.2) 4.900(0.836e28.728)
ISR No ISR
nZ 20 nZ 45
Excess stent length (mm) 2.63 0.99 2.93 1.31 0.360
Stent diameter (mm) 2.87 0.43 3.13 0.49 0.029
Abbreviations: CI, confidence interval.
Data are expressed as mean S.D. or number (%).
a Risk ratio for second group relative to the first.
b Comparison of the different stent types vs. Invastent VOLO with the lowest ISR rate as reference.
c Comparison of the different stent lengths vs. stent length (Z 7 mm) with the lowest ISR rate as reference.
Predictors for Intracranial In-stent Restenosis 503
Figure 1 A KaplaneMeier curve for neurologic event survival
function including any death, TIA, or stroke within 30 days
after the initial procedure.
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Univariate analysis
In our study, diabetes mellitus was the unique clinical
parameter associated with ISR (diabetes vs. non-diabetes:
RR, 4.143; 95% CI, 1.287e13.339, PZ 0.014), whereas age,
sex, hypertension, hyperlipidaemia, smoking, history of
coronary artery disease and time from QE to stenting were
not (Table 2).
The incidences of ISR in Mori A, Mori B and Mori C lesions
were 12%, 40.6% (Mori B vs. Mori A: RR, 5.018; 95% CI,
1.241e20.295; PZ 0.020) and 50% (Mori C vs. Mori A: RR,
7.333; 95% CI, 1.168e46.052; PZ 0.042), respectively
(Table 3); lesions with ISR had longer length than those
without ISR (PZ 0.009); the angiograms of typical cases are
shown in Fig. 3. Otherwise, lesions with irregular contour
were slightly more prone to ISR than those with smooth
contour, but this trend did not reach statistical significance
(PZ 0.066). Other angiographic lesion parameters did not
contribute to ISR (Table 3).
Considering the procedural variables, stent diameter
was statistically a significant risk factor of ISR withFigure 2 A KaplaneMeier curve for In-stent restenosis
survival function.univariate analysis. Increased ISR rate was associated with
stents that had small diameter (PZ 0.029). None of the
other procedural variables studied were associated with
increased ISR including the type of stent, stent length and
excess stent length (Table 4).
Multivariate analysis
Using stepwise multivariate Cox regression analysis, dia-
betes mellitus (HR, 2.661; 95% CI, 1.044e6.787; PZ 0.040)
and lesion length (HR, 1.206; 95% CI, 1.023e1.421;
PZ 0.026) were independently associated with increased
risk of ISR (Table 5).Discussion
The present study showed that ISR after single bare metal
balloon-mounted stent placement affected about one-third
of the intracranial lesions performed by this intervention.
Besides, we demonstrated that diabetes and lesion length
were the two independent predictors for ISR.
In this angiographic follow-up case series, ISR occurred
in 30.8% lesions, slightly lower than those reported by Sid-
diq et al15 and the Stenting of Symptomatic Atherosclerotic
Lesions in the Vertebral or Intracranial Arteries (SSYLVIA)
study5 (33.8% and 32.4%, respectively), but higher than
most of the published case series treated with balloon-
expandable stents7,9,16,17(7.5e20.25%). The ISR incidence
as estimated by the KaplaneMeier curve was 50.6% at 12
months after stenting in the present study. The differences
in patient selection, stroke risk factors, lesion distribution,
morphological characteristics of the lesion, stent type,
method of analysis and follow-up duration may explain the
variable ISR rates to some degree.
Cox regression analysis in the present study showed that
diabetes was a strong predictor for ISR after intracranial
stenting, and it was consistent with the previous published
data.5,9 Accumulating evidences showed that patients with
diabetes have a higher occurrence of ISR in coronary
stenting.18,19 Undoubtedly, the pathogenesis of ISR is
mainly characterised by neointimal hyperplasia20 and dia-
betes mellitus can enhance neointima after coronary
intervention.21 The exact mechanisms responsible for this
phenomenon remain to be uncovered, but one potential
mechanism is that diabetes promotes inflammatory cell
recruitment and abnormal extracellular matrix produc-
tion.22 However, it is unclear whether the ISR rate can be
reduced by improved metabolic control in diabetes. Further
studies are required to elucidate the effect of strict gly-
caemic control on ISR rates in diabetic patients.
The other strong independent predictor for ISR identi-
fied in our study was lesion length. In the recent long-term
follow-up study of middle cerebral artery stenting, Miao
et al.9 also found a trend towards a greater rate of ISR in
long-lesion, although this trend did not reach statistical
significance. In addition, lesion length has also been sug-
gested having great predictive value for ISR in the coronary
intervention and vertebral artery origin stenting.23,24 A
longer lesion means greater plaque burden and increased
probability of smooth muscle cell proliferation and migra-
tion to neointima,25 which may be one of the underlying
mechanisms leading to the intracranial ISR.
Figure 3 A 65-year-old man initial presented with a left MCA distribution stroke. (A) Angiogram showed a tubular (7.5 mm in
length) and eccentric 85% stenosis (Mori B type) at M1 segment of the left MCA (white arrow). (B) After a mounted-balloon stent
implantation, angiogram demonstrated 15% residual stenosis. The dual antiplatelet regimen (aspirin and clopidogrel) was usually
maintained. (C) The 6-month follow-up angiogram shows complete occlusion within the stented segment of the MCA. The patient
remains asymptomatic; no repeat angioplasty was performed. (D) The other patient was a 72-year-old man with posterior circu-
lation transient ischaemic attacks. Initial angiogram demonstrated a short (4.2 mm in length), ulcerative, and eccentric 70%
stenosis (Mori A type) of the distal vertebral artery (black arrow). (E) After a mounted-balloon stent placement, angiogram
demonstrated no residual stenosis. (F) The 27-month follow-up angiogram shows no ISR in the region of the originally stented
lesion.
Predictors for Intracranial In-stent Restenosis 505Mori classification was initially developed to predict the
risk of clinical complications and restenosis after intracra-
nial primary angioplasty.11 Mori A lesions tend to have
better clinical and angiographic outcomes than Mori B and
Mori C lesions, which are longer, more eccentric, severer
angulated and more occlusive. In the present study, it was
also found that the Mori B or Mori C lesions had higher rate
of ISR than Mori A lesions by univariate analysis. However,
the similar results were not observed by multivariate
analysis, possibly because the number of Mori C lesions was
small.
In the present study, stent diameter was, on average,
slightly (0.26 mm) smaller in patients with ISR. The stentTable 5 Independent risk factors associated with ISR using step
Factors B SE Wald
Diabetes (yes vs. no) 0.979 0.478 4.20
Lesion length (mm) 0.187 0.084 4.96
Stent diameter (mm) 1.059 0.593 3.18
Abbreviations: CI, confidence interval; B, Regression coefficient; SE,was chosen on the basis of the diameter of the smallest
normal parent vessel, thus providing a surrogate indicator
of vessel size. Previous studies suggested that ISR after
intracranial stenting was associated with smaller vessels
treated in their case series.5,7 Our study also showed that
the smaller vessels were more susceptible to ISR using
univariate analysis; however, this factor was not detected
as a significant independent predictor for ISR (PZ 0.074) by
multivariate analysis. In addition, a recent report failed to
show a relation between stent length or stent type and
intracranial ISR.9 Previous studies identified that various
stent designs, multiple stents, stent length, excess stent
length and overlapping stents were independent predictorswise multivariate Cox regression analysis.
P Value Hazard ratio 95% CI
0 0.040 2.661 1.044e6.787
1 0.026 1.206 1.023e1.421
7 0.074 0.347 0.108e1.109
Standard Error of B.
506 S.G. Zhu et al.for ISR after coronary intervention.23,26,27 The present
analysis of lesions receiving single stent of variable length
eliminates the potential confounding influence of multiple
stents and stent overlap on ISR, but stent length and excess
stent length were not still found to be risk factors for ISR.
Several limitations of the current study should be
considered. First, the stents used are not standardised in
that only a minority of intracranial lesions were treated
with dedicated intracranial stents and the majority were
placed by non-dedicated intracranial stents designed for
coronary arteries. This may influence potentially rate of
restenosis and clinical complications. Second, the total
number of patients is relatively small and angiographic
follow-up of all patients is incomplete, which may thus
limit statistical power and bias our results in this retro-
spective and single-centre study. Clearly, prospective and
multi-centre studies including larger sample size are
needed to confirm the results of the present study.
In conclusion, symptomatic intracranial atherosclerotic
stenosis can be treated safely and effectively with bare
metal balloon-mounted stents. However, ISR after intra-
cranial stenting with bare metal balloon-mounted stents in
our study seems to be more frequent than those reported
by the majority of previous series studies, and is associated
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